In a previous study, ERG upregulation is seen in about half of all prostate cancer patients, and combining human prostate cancer genetics with transgenic mice showed that PTEN loss occurs concomitantly with ERG aberrant expression [29,30]. Here, PTEN is linked to prostate carcinoma.